FDA: HIV Drug Lexiva Label to Warn of Cholesterol Increases
December 4, 2009
GlaxoSmithKline PLC has written to doctors regarding label changes in its HIV drug Lexiva. The letter, which the Food and Drug Administration posted on its Web site Thursday, warns of increases in cholesterol levels and discusses a "potential" increase in heart attacks. GSK recommended that doctors check patients' cholesterol and triglyceride levels before and during treatment with Lexiva, and that patients also be monitored for high blood pressure, diabetes, and smoking. To read the letter, click here.
12.03.2009; Jennifer Corbett Dooren, Dow Jones Newswires
GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S.